SCHEMBL13900239

SCHEMBL13900239

CCCN(CC(C)(C)C)C(=O)Nc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HDAC6 Q9UBN7 5/20 0.50
HDAC1 Q13547 4/20 0.50
HDAC3 O15379 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
EGFR P00533 2/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA9 Q16790 2/20 0.49
CA2 P00918 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10596118 0.87 ALDH1A1 (0.61) ALDH1A1NPSR1HDAC6HDAC1HDAC3
SCHEMBL14200299 0.87 CA12 (0.51) ALDH1A1NPSR1HDAC6HDAC1HDAC3
SCHEMBL13900722 0.85 MEN1 (0.55) ALDH1A1HDAC6HDAC1HDAC3HDAC2
SCHEMBL25230837 0.84 NPSR1 (0.60) ALDH1A1NPSR1HDAC6HDAC1HDAC3
SCHEMBL13900720 0.83 NPC1 (0.47) ALDH1A1MEN1KMT2ATP53KDM4E
SCHEMBL14228915 0.81 HDAC6 (0.62) ALDH1A1NPSR1HDAC6HDAC1HDAC3
SCHEMBL13900736 0.81 L3MBTL1 (0.50) ALDH1A1NPSR1CA12CA9MEN1
SCHEMBL13900760 0.79 RIPK1 (0.50) ALDH1A1NPSR1HDAC6HDAC1CA12
SCHEMBL14200302 0.78 HDAC6 (0.56) ALDH1A1NPSR1HDAC6HDAC1HDAC3
SCHEMBL2448810 0.78 HDAC6 (0.65) ALDH1A1NPSR1HDAC6HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504391-B2 Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders SCHERING CORPORATION (US) 2009-03-17 US disclosed